Yet the stock has lost 24% this year, underperforming its peers in the MSCI World pharmaceuticals and biotech index.

FORBES: Bargain bourses

In two years the American Stock Exchange Biotech index has collapsed 60%.

FORBES: Biopipeline

While the American Stock Exchange's pharmaceutical index has sunk some 5% in the past six months, its biotech index has risen by 10%.

FORBES: Big Pharma's Ails Could Spread To Biotech

The Nasdaq Biotech Index is up 42% year to date, fueled in large part by successful clinical trials of several experimental drugs that were proven effective in stopping the spread of cancer.

FORBES: Magazine Article